Search

Your search keyword '"Barritt, A. Sidney"' showing total 140 results
Start Over Author "Barritt, A. Sidney" Search Limiters Full Text
140 results on '"Barritt, A. Sidney"'

1. Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study

Author

Thomson, Mary J, Serper, Marina, Khungar, Vandana, Weiss, L Michael, Trinh, Huy, Firpi-Morell, Roberto, Roden, Michael, Loomba, Rohit, Barritt, A Sidney, Gazis, Derek, Mospan, Andrea R, Fried, Michael W, Reddy, K Rajender, and Lok, Anna S

Subjects
Cardiovascular, Chronic Liver Disease and Cirrhosis, Liver Disease, Prevention, Clinical Research, Rare Diseases, Hepatitis, Digestive Diseases, Oral and gastrointestinal, Good Health and Well Being, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Liver Cirrhosis, Liver Neoplasms, Non-alcoholic Fatty Liver Disease, Prevalence, Clinical Sciences, Gastroenterology & Hepatology
Abstract

Patients with nonalcoholic fatty liver disease (NAFLD) are at an increased risk of cardiovascular disease. Hydoxy-3-methyglutaryl-coenzyme reductase inhibitors, statins, reduce the risk of cardiovascular events.1 Studies have shown that statins are safe among patients with liver disease, including those with compensated cirrhosis,2 and their use is associated with lower mortality, hepatic decompensation, and possibly hepatocellular carcinoma.3,4 Despite these data, statins are under prescribed among patients with liver disease due to concerns about hepatotoxicity.5 This study aimed to assess prevalence and patient factors associated with indicated statin use in patients with NAFLD in a real-world cohort.

Published
2022

3. Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET‐NASH Study

Author

Barritt, A Sidney, Watkins, Stephanie, Gitlin, Norman, Klein, Samuel, Lok, Anna S, Loomba, Rohit, Schoen, Cheryl, Reddy, K Rajender, Trinh, Huy Ngoc, Mospan, Andrea R, Vos, Miriam B, Weiss, L Michael, Cusi, Kenneth, Neuschwander‐Tetri, Brent A, and Sanyal, Arun J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Liver Disease, Digestive Diseases, Chronic Liver Disease and Cirrhosis, Hepatitis, Clinical Research, Good Health and Well Being, Clinical sciences
Abstract

Much of the current data on nonalcoholic fatty liver disease (NAFLD) are derived from biopsy-based studies that may introduce ascertainment and selection bias. Selection of patients for liver biopsy has implications for clinical practice and the reported epidemiology of NAFLD. The aim of this study was to determine patient factors predictive of histologic versus empiric clinical diagnosis of NAFLD in real-world practice. Adults from TARGET-NASH were included in this study. Descriptive statistics are provided for the cohort and compare the characteristics of histologic NAFLD versus patients with clinically diagnosed NAFLD, followed by logistic regression and machine-learning models to describe predictors of liver biopsy. The records of 3,474 subjects were analyzed; median age was 59 years, 59% were female, 75% were White, and median body mass index was 32 kg/m2. Using histologic and/or clinical criteria, a diagnosis of nonalcoholic steatohepatitis was made in 37%, and cirrhosis in 33%. Comorbid conditions included cardiovascular disease (19%), mental health diagnoses (49%), and osteoarthritis (10%). Predictors of a biopsy diagnosis included White race, female sex, diabetes, and elevated alanine aminotransferase (ALT). ALT increased the odds of liver biopsy by 14% per 10-point rise. Machine-learning analyses showed non-White patients with ALT

Published
2021

4. Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort

Author

Abdelmalek, Manal, Aguilar, Humberto, Ahmed, Aijaz, Allen, Alina, Barlow, Sarah, Barritt, Sid, Bernstein, David, Bhamidimarri, Kaylan, Billings, Liana, Brown, Kyle, Brown, Robert, Corbin, Karen, Cusi, Kenneth, deLemos, Andrew, Emerick, Karan, Firpi-Morell, Roberto, Ghali, Maged Adel, Henry, Zachary, Jackson, Whitney, Janardhan, Sujit, Kabbany, Mohammad, Kemmer, Nyingi, Koch, David, Kupec, Justin, Landis, Charles, Lawrence, Mary Katherine, Levy, Cynthia, Lidofsky, Steven, Lok, Anna, Luketic, Velimir, Martinez, Enrique, McClain, Craig, McKiernan, Patrick, Mitchell, Ellen, Noureddin, Mazen, Palle, Sirish, Pham, Yen, Pound, David, Reddy, Rajender, Regenstein, Fredric, Rinella, Mary, Rochling, Fedja, Rudolph, Bryan, Rustgi, Vinod, Said, Adnan, Samala, Niharika, Sarkar, Souvik, Sherman, Kenneth, Shiffman, Mitchell, Smith, Coleman, Taunk, Jawahar, Tetri, Brent, Thuluvath, Paul, Trinh, Huy, Verna, Elizabeth, Vos, Miriam, Weiss, L. Michael, Wong, Mark, Wyne, Kathleen, Xanthakos, Stavra, Sanyal, Arun J., Munoz, Breda, Barritt, A. Sidney, IV, Muthiah, Mark, Mospan, Andrea R., Reddy, K. Rajender, Thuluvath, Paul J., Bhamidimarri, Kalyan Ram, and Fried, Michael W.

Published
2023
Full Text
View/download PDF

7. HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition

Author

Niu, Jianghe, Javaid, Asad, Nasir, Bilal, Susheela, Ammu, Nasser, Imad, Rusibamayila, Nifasha, Foley, Cara, Stahler, Alisha C., Stadheim, Linda, Lake, John, Lacher, Philip, Rushing, Kathryn, Nagy, Rosemary A., Cerkoski, Jacki, DeMarco Shaw, Debra, Kessels, Lisa, Klebert, Michael K., Noureldin, Seham, La, Danie, Liu, Lucie, Kaznowski, Diana, Chen, Jiayun, Vladutu, Doinita, Cerocchi, Orlando, Rowan, Debra, Bass, Sheila, Lilly, Barbara, French, Samuel, Peacock, Velma, Shobe, Ashley, Davis, Rayshawnda, Kuras, Romuald, Ayala, Claudia, Lau, Ivy, Podolskaya, Veronika, von Bakonyi, Anna, DeVole, Nata, McKenna, Barbara, Choi, Karen, Oberhelman, Kelly, Kaza, Sravanthi, Bowen, Abigail, Kalathil, Sumodh, Huddleston, Leslie, Wong, Richmond, Barritt, A. Sidney, Marsh, Tiffany, Metheny, Vikki, Cardona, Danielle, Luketic, Velimir A., Smith, Paula G., Hofmann, Charlotte, Wolfstone, Alycia, Mooney, Jody, Cardona-Gonzalez, Lupita, Fryzek, Nancy, Rivera, Elenita, Morris, Nevitt, Haynes-Williams, Vanessa, Huang, Amy, Sherker, Averell H., Torrance, Rebecca J., Hall, Sherry R., Valiga, Mary E., Torrey, Keith, Levine, Danielle, Keith, James, Betts, Michael, Montaner, Luis J., Averbach, Frani, Haller, Tamara, Hardison, Regina, Kelley, Stephanie, Lawlor, Sharon, Lin, Hsing-Hua (Sylvia), Liu, Stephen, Lombardero, Manuel, Pelesko, Andrew, Stoliker, Donna, Weiner, Melissa, Zadorozny, Ella, Brouwer, Willem P., Zhao, Qian, Hansen, Bettina E., Lau, Daryl, Khalili, Mandana, Terrault, Norah A., Di Bisceglie, Adrian M., Perrillo, Robert P., Fried, Michael W., Wong, David, Feld, Jordan J., Belle, Steven H., and Janssen, Harry L.A.

Published
2020
Full Text
View/download PDF

8. Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype

Author

Ghany, Marc G, Perrillo, Robert, Li, Ruosha, Belle, Steven H, Janssen, Harry LA, Terrault, Norah A, Shuhart, Margaret C, Lau, Daryl T-Y, Kim, W Ray, Fried, Michael W, Sterling, Richard K, Di Bisceglie, Adrian M, Han, Steven-Huy B, Ganova-Raeva, Lilia Milkova, Chang, Kyong-Mi, Lok, Anna Suk-Fong, Network, Hepatitis B Research, Chung, Raymond T, Roberts, Lewis R, Smith, Coleman I, Lisker-Melman, Mauricio, Wong, David K, Juan, Joshua, Feld, Jordan, Yim, Colina, Heathcoate, Jenny, Lee, William M, Do, Son, Tran, Tram T, Khalili, Mandana, Cooper, Stewart L, Fontana, Robert J, Tsai, Naoky, Patel, Keyur, Evon, Donna, Carithers, Robert C, Kowdley, Kris V, Wang, Chia C, Liang, T Jake, Park, Jang-June, Wahed, Abdus, Kleiner, David, Afdhal, Nezam, Javaid, Asad, Niu, Jianghe, Han, Johanna, Nasser, Imad, Stahler, Alisha C, Stadheim, Linda, Hassan, Mohamed, King, Debra L, Nagy, Rosemary A, La, Danie, Liu, Lucie, Minshall, Stacey, Bass, Sheila, French, Samuel, Peacock, Velma, Ungermann, Ashley, Ayala, Claudia, Olson, Emma, Lau, Ivy, Podolskaya, Veronika, DeVole, Nata, McKenna, Barbara, Oberhelman, Kelly, Kaza, Sravanthi, Rodd, Cassandra, Huddleston, Leslie, Poerzgen, Peter, Darling, Jama M, Barritt, A Sidney, Marsh, Tiffany, Metheny, Vikki, Cardona, Danielle, Luketic, Velimir A, Smith, Paula G, Hofmann, Charlotte, Mathisen, Terri, Strom, Susan, Mooney, Jody, Cardona-Gonzalez, Lupita, Fryzek, Nancy, Rivera, Elenita, Morris, Nevitt, Haynes-Williams, Vanessa, Valiga, Mary E, Torrey, Keith, Levine, Danielle, Keith, James, Betts, Michael, Montaner, Luis J, Teo, Chong-Gee, Khudyakov, Yury, Punkova, Lili T, Cloonan, Yona, Danielson, Michelle, Haller, Tamara, Johnson, Geoffrey, and Kelley, Stephanie

Subjects
Liver Disease, Infectious Diseases, Hepatitis, Digestive Diseases, Chronic Liver Disease and Cirrhosis, Hepatitis - B, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Canada, Emigrants and Immigrants, Female, Genotype, Hepatitis B virus, Hepatitis B, Chronic, Humans, Male, Middle Aged, United States, Young Adult, HBeAg, Chronic Hepatitis B Virus Infection, USA, ALT, Hepatitis B Research Network, Clinical Sciences, Gastroenterology & Hepatology
Abstract

Background & aimsChronic hepatitis B virus (HBV) infection is an important cause of cirrhosis and hepatocellular carcinoma worldwide; populations that migrate to the United States and Canada might be affected disproportionately. The Hepatitis B Research Network (HBRN) is a cooperative network of investigators from the United States and Canada, created to facilitate clinical, therapeutic, and translational research in adults and children with hepatitis B. We describe the structure of the network and baseline characteristics of adults with hepatitis B enrolled in the network.MethodsThe HBRN collected data on the clinical characteristics of 1625 adults with chronic HBV infection who are not receiving antiviral therapy from 21 clinical centers in North America.ResultsHalf of the subjects in the HBRN are men, and the median age is 42 years; 72% are Asian, 15% are black, and 11% are white; with 82% born outside of North America. The most common HBV genotype was B (39%); 74% of subjects were negative for the hepatitis B e antigen. The median serum level of HBV DNA when the study began was 3.6 log10 IU/mL; 68% of male subjects and 67% of female subjects had alanine aminotransferase levels higher than the normal range.ConclusionsThe HBRN cohort is used to address important clinical and therapeutic questions for North Americans infected with chronic HBV and to guide health policies on HBV prevention and management in North America.

Published
2015

9. Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide

Author

Shah, Neil D., Ventura-Cots, Meritxell, Abraldes, Juan G., Alboraie, Mohamed, Alfadhli, Ahmad, Argemi, Josepmaria, Badia-Aranda, Ester, Arús-Soler, Enrique, Barritt, A. Sidney, IV, Bessone, Fernando, Biryukova, Marina, Carrilho, Flair J., Fernández, Marlen Castellanos, Dorta Guiridi, Zaily, El Kassas, Mohamed, Eng-Kiong, Teo, Queiroz Farias, Alberto, George, Jacob, Gui, Wenfang, Thurairajah, Prem H., Hsiang, John Chen, Husić-Selimovic, Azra, Isakov, Vasily, Karoney, Mercy, Kim, Won, Kluwe, Johannes, Kochhar, Rakesh, Dhaka, Narendra, Costa, Pedro Marques, Nabeshima Pharm, Mariana A., Ono, Suzane K., Reis, Daniela, Rodil, Agustina, Domech, Caridad Ruenes, Sáez-Royuela, Federico, Scheurich, Christoph, Siow, Way, Sivac-Burina, Nadja, Dos Santos Traquino, Edna Solange, Some, Fatma, Spreckic, Sanjin, Tan, Shiyun, Vorobioff, Julio, Wandera, Andrew, Wu, Pengbo, Yacoub, Mohamed, Yang, Ling, Yu, Yuanjie, Zahiragic, Nerma, Zhang, Chaoqun, Cortez-Pinto, Helena, and Bataller, Ramon

Published
2019
Full Text
View/download PDF

10. Patient-reported symptoms and interest in symptom monitoring in HCC treated with locoregional therapies: A qualitative study

Author

Moon, Andrew M., primary, Cook, Sarah, additional, Swier, Rachel M., additional, Sanoff, Hanna K., additional, Kappelman, Michael D., additional, Wagner, Lynne I., additional, Barritt, A. Sidney, additional, Singal, Amit G., additional, Shah, Neil D., additional, Mauro, David M., additional, Yanagihara, Ted K., additional, Gerber, David A., additional, Fried, Michael W., additional, Brown, Cristal, additional, Waheed, Myra, additional, Teal, Randall, additional, and Evon, Donna M., additional

Published
2023
Full Text
View/download PDF

11. Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort

Author

Sanyal, Arun J., primary, Munoz, Breda, additional, Cusi, Kenneth, additional, Barritt, A. Sidney, additional, Muthiah, Mark, additional, Mospan, Andrea R., additional, Reddy, K. Rajender, additional, Firpi-Morell, Roberto, additional, Thuluvath, Paul J., additional, Bhamidimarri, Kalyan Ram, additional, Fried, Michael W., additional, Abdelmalek, Manal, additional, Aguilar, Humberto, additional, Ahmed, Aijaz, additional, Allen, Alina, additional, Barlow, Sarah, additional, Barritt, Sid, additional, Bernstein, David, additional, Bhamidimarri, Kaylan, additional, Billings, Liana, additional, Brown, Kyle, additional, Brown, Robert, additional, Corbin, Karen, additional, deLemos, Andrew, additional, Emerick, Karan, additional, Ghali, Maged Adel, additional, Henry, Zachary, additional, Jackson, Whitney, additional, Janardhan, Sujit, additional, Kabbany, Mohammad, additional, Kemmer, Nyingi, additional, Koch, David, additional, Kupec, Justin, additional, Landis, Charles, additional, Lawrence, Mary Katherine, additional, Levy, Cynthia, additional, Lidofsky, Steven, additional, Lok, Anna, additional, Luketic, Velimir, additional, Martinez, Enrique, additional, McClain, Craig, additional, McKiernan, Patrick, additional, Mitchell, Ellen, additional, Noureddin, Mazen, additional, Palle, Sirish, additional, Pham, Yen, additional, Pound, David, additional, Reddy, Rajender, additional, Regenstein, Fredric, additional, Rinella, Mary, additional, Rochling, Fedja, additional, Rudolph, Bryan, additional, Rustgi, Vinod, additional, Said, Adnan, additional, Samala, Niharika, additional, Sarkar, Souvik, additional, Sherman, Kenneth, additional, Shiffman, Mitchell, additional, Smith, Coleman, additional, Taunk, Jawahar, additional, Tetri, Brent, additional, Thuluvath, Paul, additional, Trinh, Huy, additional, Verna, Elizabeth, additional, Vos, Miriam, additional, Weiss, L. Michael, additional, Wong, Mark, additional, Wyne, Kathleen, additional, and Xanthakos, Stavra, additional

Published
2023
Full Text
View/download PDF

12. Hepatocellular Carcinoma Surveillance Among Individuals with Cirrhosis: Trends by Payer, Etiology and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010-2018

Author

Hsu, Christine D., primary, Henderson, Louise M., additional, Jackson, Bradford E., additional, Baggett, Christopher D., additional, Jonsson Funk, Michele, additional, Olshan, Andrew F., additional, Gupta, Parul, additional, Barritt, A Sidney., additional, Sanoff, Hanna K., additional, Wheeler, Stephanie B., additional, Moon, Andrew M., additional, and Lund, Jennifer L., additional

Published
2023
Full Text
View/download PDF

15. Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype

Author

Chung, Raymond T., Roberts, Lewis R., Smith, Coleman I., Lisker-Melman, Mauricio, Wong, David K., Juan, Joshua, Feld, Jordan, Yim, Colina, Heathcoate, Jenny, Lee, William M., Do, Son, Tran, Tram T., Khalili, Mandana, Cooper, Stewart L., Fontana, Robert J., Tsai, Naoky, Patel, Keyur, Evon, Donna, Carithers, Robert C., Kowdley, Kris V., Wang, Chia C., Liang, T. Jake, Park, Jang-June, Wahed, Abdus, Kleiner, David, Afdhal, Nezam, Javaid, Asad, Niu, Jianghe, Han, Johanna, Nasser, Imad, Stahler, Alisha C., Stadheim, Linda, Hassan, Mohamed, King, Debra L., Nagy, Rosemary A., La, Danie, Liu, Lucie, Minshall, Stacey, Bass, Sheila, French, Samuel, Peacock, Velma, Ungermann, Ashley, Ayala, Claudia, Olson, Emma, Lau, Ivy, Podolskaya, Veronika, DeVole, Nata, McKenna, Barbara, Oberhelman, Kelly, Kaza, Sravanthi, Rodd, Cassandra, Huddleston, Leslie, Poerzgen, Peter, Darling, Jama M., Barritt, A. Sidney, Marsh, Tiffany, Metheny, Vikki, Cardona, Danielle, Luketic, Velimir A., Smith, Paula G., Hofmann, Charlotte, Mathisen, Terri, Strom, Susan, Mooney, Jody, Cardona-Gonzalez, Lupita, Fryzek, Nancy, Rivera, Elenita, Morris, Nevitt, Haynes-Williams, Vanessa, Valiga, Mary E., Torrey, Keith, Levine, Danielle, Keith, James, Betts, Michael, Montaner, Luis J., Teo, Chong-Gee, Khudyakov, Yury, Punkova, Lili T., Cloonan, Yona, Danielson, Michelle, Haller, Tamara, Johnson, Geoffrey, Kelley, Stephanie, Lawlor, Sharon, Li, Ruosha, Lombardero, Manuel, MacGregor, Joan M., Pelesko, Andrew, Stoliker, Donna, Walters, Barbara, Zadorozny, Ella, Ghany, Marc G., Perrillo, Robert, Belle, Steven H., Janssen, Harry L.A., Terrault, Norah A., Shuhart, Margaret C., Lau, Daryl T.-Y., Kim, W. Ray, Fried, Michael W., Sterling, Richard K., Di Bisceglie, Adrian M., Han, Steven-Huy B., Ganova-Raeva, Lilia Milkova, Chang, Kyong-Mi, and Lok, Anna Suk-Fong

Published
2015
Full Text
View/download PDF

17. A Histologic Scoring System for Prognosis of Patients With Alcoholic Hepatitis

Author

Altamirano, José, Miquel, Rosa, Katoonizadeh, Aezam, Abraldes, Juan G., Duarte–Rojo, Andrés, Louvet, Alexandre, Augustin, Salvador, Mookerjee, Rajeshwar P., Michelena, Javier, Smyrk, Thomas C., Buob, David, Leteurtre, Emmanuelle, Rincón, Diego, Ruiz, Pablo, García–Pagán, Juan Carlos, Guerrero–Marquez, Carmen, Jones, Patricia D., Barritt, A. Sidney, IV, Arroyo, Vicente, Bruguera, Miquel, Bañares, Rafael, Ginès, Pere, Caballería, Juan, Roskams, Tania, Nevens, Frederik, Jalan, Rajiv, Mathurin, Philippe, Shah, Vijay H., and Bataller, Ramón

Published
2014
Full Text
View/download PDF

20. EP1206: LIVER INJURY ASSOCIATED WITH TURMERIC–A GROWING PROBLEM: NINE CASES FROM THE DRUG-INDUCED LIVER INJURY NETWORK [DILIN]

Author

Marzio, Dina Halegoua-De, primary, Navarro, Victor, additional, Hoofnagle, Jay, additional, Ahmad, Jawad, additional, Avula, Bharathi, additional, Barnhart, Huiman, additional, Barritt, A. Sidney, additional, Bonkovsky, Herbert L., additional, Fontana, Robert J., additional, Ghabril, Marwan S., additional, Khan, Ikhlas A., additional, Phillip, Elizabeth, additional, Stolz, Andrew, additional, and Vuppalanchi, Raj, additional

Published
2022
Full Text
View/download PDF

21. Tu1258: EFFECTIVENESS OF COVID-19 VIRAL VECTOR JANSSEN AD.26.COV2.S VACCINE AND COMPARISON WITH MRNA VACCINES IN CIRRHOSIS

Author

John, Binu V., primary, Doshi, Akash, additional, Deng, Yangyang, additional, Mansour, Natalie, additional, Barritt, Alfred Sidney, additional, Moon, Andrew M., additional, Ioannou, George N., additional, Martin, Paul, additional, Chao, Hann-Hsiang, additional, Taddei, Tamar H., additional, Kaplan, David E., additional, and Dahman, Bassam, additional

Published
2022
Full Text
View/download PDF

23. SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and Outcomes.

Author

Baldelli, Luke, Marjot, Thomas, Barnes, Eleanor, Barritt, A. Sidney, Webb, Gwilym J., and Moon, Andrew M.

Subjects
SARS-CoV-2, COVID-19, LIVER diseases, BILIARY atresia
Abstract

The impact of the coronavirus disease 2019 (COVID-19) pandemic has been immense, and it continues to have lasting repercussions. While the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus primarily infects the respiratory system, other organ systems are affected, including the liver. Scientific knowledge on the role of SARS-CoV-2 infection and liver injury has evolved rapidly, with recent data suggesting specific hepatotropism of SARS-CoV-2. Moreover, additional concerns have been raised in regard to long-term liver damage, related to emerging cases of post-COVID-19 cholangiopathy and chronic cholestasis. Great effort has also been focused on studying how specific subpopulations with chronic medical conditions might be disproportionately impacted by COVID-19. One such population includes individuals with chronic liver disease (CLD) and cirrhosis, with an expanding body of research indicating these patients being particularly susceptible to adverse outcomes. In this review, we provide an updated summary on the current pathogenesis and mechanism of liver injury in the setting of SARS-CoV-2 infection, the association between health outcomes and SARS-CoV-2 infection in patients with CLD, and the unique consequences of the COVID-19 pandemic on the routine care of patients with CLD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. SARS‐CoV‐2 Infections Among Patients With Liver Disease and Liver Transplantation Who Received COVID‐19 Vaccination

Author

Moon, Andrew M., primary, Webb, Gwilym J., additional, García‐Juárez, Ignacio, additional, Kulkarni, Anand V., additional, Adali, Gupse, additional, Wong, David K., additional, Lusina, Beth, additional, Dalekos, George N., additional, Masson, Steven, additional, Shore, Brandon M., additional, Barnes, Eleanor, additional, Barritt, A. Sidney, additional, and Marjot, Thomas, additional

Published
2021
Full Text
View/download PDF

29. SARS‐CoV‐2 Infections Among Patients With Liver Disease and Liver Transplantation Who Received COVID‐19 Vaccination.

Author

Moon, Andrew M., Webb, Gwilym J., García‐Juárez, Ignacio, Kulkarni, Anand V., Adali, Gupse, Wong, David K., Lusina, Beth, Dalekos, George N., Masson, Steven, Shore, Brandon M., Barnes, Eleanor, Barritt, A. Sidney, and Marjot, Thomas

Subjects
SARS-CoV-2, COVID-19 vaccines, COVID-19, LIVER transplantation, LIVER diseases
Abstract

Many safe and effective severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccinations dramatically reduce risks of coronavirus disease 2019 (COVID‐19) complications and deaths. We aimed to describe cases of SARS‐CoV‐2 infection among patients with chronic liver disease (CLD) and liver transplant (LT) recipients with at least one prior COVID‐19 vaccine dose. The SECURE‐Liver and COVID‐Hep international reporting registries were used to identify laboratory‐confirmed COVID‐19 in CLD and LT patients who received a COVID‐19 vaccination. Of the 342 cases of lab‐confirmed SARS‐CoV‐2 infections in the era after vaccine licensing, 40 patients (21 with CLD and 19 with LT) had at least one prior COVID‐19 vaccination, including 12 who were fully vaccinated (≥2 weeks after second dose). Of the 21 patients with CLD (90% with cirrhosis), 7 (33%) were hospitalized, 1 (5%) was admitted to the intensive care unit (ICU), and 0 died. In the LT cohort (n = 19), there were 6 hospitalizations (32%), including 3 (16%) resulting in mechanical ventilation and 2 (11%) resulting in death. All three cases of severe COVID‐19 occurred in patients who had a single vaccine dose within the last 1‐2 weeks. In contemporary patients with CLD, rates of symptomatic infection, hospitalization, ICU admission, invasive ventilation, and death were numerically higher in unvaccinated individuals. Conclusion: This case series demonstrates the potential for COVID‐19 infections among patients with CLD and LT recipients who had received the COVID‐19 vaccination. Vaccination against SARS‐CoV‐2 appears to result in favorable outcomes as attested by the absence of mechanical ventilation, ICU, or death among fully vaccinated patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

33. HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition

Author

Brouwer, Willem P., primary, Zhao, Qian, additional, Hansen, Bettina E., additional, Lau, Daryl, additional, Khalili, Mandana, additional, Terrault, Norah A., additional, Di Bisceglie, Adrian M., additional, Perrillo, Robert P., additional, Fried, Michael W., additional, Wong, David, additional, Feld, Jordan J., additional, Belle, Steven H., additional, Janssen, Harry L.A., additional, Niu, Jianghe, additional, Javaid, Asad, additional, Nasir, Bilal, additional, Susheela, Ammu, additional, Nasser, Imad, additional, Rusibamayila, Nifasha, additional, Foley, Cara, additional, Stahler, Alisha C., additional, Stadheim, Linda, additional, Lake, John, additional, Lacher, Philip, additional, Rushing, Kathryn, additional, Nagy, Rosemary A., additional, Cerkoski, Jacki, additional, DeMarco Shaw, Debra, additional, Kessels, Lisa, additional, Klebert, Michael K., additional, Noureldin, Seham, additional, La, Danie, additional, Liu, Lucie, additional, Kaznowski, Diana, additional, Chen, Jiayun, additional, Vladutu, Doinita, additional, Cerocchi, Orlando, additional, Rowan, Debra, additional, Bass, Sheila, additional, Lilly, Barbara, additional, French, Samuel, additional, Peacock, Velma, additional, Shobe, Ashley, additional, Davis, Rayshawnda, additional, Kuras, Romuald, additional, Ayala, Claudia, additional, Lau, Ivy, additional, Podolskaya, Veronika, additional, von Bakonyi, Anna, additional, DeVole, Nata, additional, McKenna, Barbara, additional, Choi, Karen, additional, Oberhelman, Kelly, additional, Kaza, Sravanthi, additional, Bowen, Abigail, additional, Kalathil, Sumodh, additional, Huddleston, Leslie, additional, Wong, Richmond, additional, Barritt, A. Sidney, additional, Marsh, Tiffany, additional, Metheny, Vikki, additional, Cardona, Danielle, additional, Luketic, Velimir A., additional, Smith, Paula G., additional, Hofmann, Charlotte, additional, Wolfstone, Alycia, additional, Mooney, Jody, additional, Cardona-Gonzalez, Lupita, additional, Fryzek, Nancy, additional, Rivera, Elenita, additional, Morris, Nevitt, additional, Haynes-Williams, Vanessa, additional, Huang, Amy, additional, Sherker, Averell H., additional, Torrance, Rebecca J., additional, Hall, Sherry R., additional, Valiga, Mary E., additional, Torrey, Keith, additional, Levine, Danielle, additional, Keith, James, additional, Betts, Michael, additional, Montaner, Luis J., additional, Averbach, Frani, additional, Haller, Tamara, additional, Hardison, Regina, additional, Kelley, Stephanie, additional, Lawlor, Sharon, additional, Lin, Hsing-Hua (Sylvia), additional, Liu, Stephen, additional, Lombardero, Manuel, additional, Pelesko, Andrew, additional, Stoliker, Donna, additional, Weiner, Melissa, additional, and Zadorozny, Ella, additional

Published
2020
Full Text
View/download PDF

35. Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis.

Author

Kim, Hannah P., Idowu, Michael O., Mospan, Andrea R., Allmon, Andrew G., Roden, Michael, Newsome, Philip, Lok, Anna S., Thuluvath, Paul J., Taunk, Jawahar, Fried, Michael W., Sanyal, Arun J., Barritt, A. Sidney, Abdelmalek, Manal, Aguilar, Humberto, Ahmed, Aijaz, Allen, Alina, Barlow, Sarah, Barritt, Sid, Bernstein, David, and Bhamidimarri, Kaylan

Subjects
LIVER biopsy, DIAGNOSIS, NON-alcoholic fatty liver disease, FATTY liver, TYPE 2 diabetes
Abstract

Summary: Background: Patients with non‐alcoholic steatohepatitis (NASH) and fibrosis stage ≥2 comprise a target population for pharmacotherapy. Liver biopsy, the reference standard for identifying this population, requires complete and accurate assessment of steatohepatitis and fibrosis. Aims To investigate the completeness of real‐world NASH‐related pathology reports, assess concordance between site pathologists and central expert interpretation of the histologic elements of NASH, and determine concordance between biopsy‐diagnosed NASH and a pragmatic clinical definition of NASH. Methods: Liver pathology reports from 222 patients across 38 TARGET‐NASH sites were analysed for documentation of the histologic features of NASH. Biopsy slides were over‐read by a blinded central expert pathologist. Concordance of histologic scores and interpretation was assessed. Histologic concordance with a clinical definition of NASH was determined. TARGET‐NASH clinically defined NASH: elevated ALT, hepatic steatosis on biopsy or imaging and ≥1 of the following: BMI ≥30 kg/m2, type 2 diabetes mellitus and dyslipidaemia. Results: Documentation of steatosis, lobular inflammation, portal inflammation and ballooning were missing from 21%, 35%, 46% and 40% of reports, respectively. There was slight‐to‐fair concordance (weighted kappa 0.01‐0.35) between site and central pathologists for inflammatory features, and moderate concordance (weighted kappa 0.56‐0.57) for fibrosis staging. Clinical definition of NASH was 75%‐91% concordant (94%‐95% sensitive) with biopsy‐diagnosed NASH. Conclusions: There is substantial variability in reporting and grading NASH and fibrosis staging in clinical practice. This heterogeneity may adversely impact patient assessment and translation of practice guidelines into reality. The TARGET‐NASH pragmatic clinical definition may serve as a valuable tool to accurately identify NASH patients in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

36. Randomized Controlled Trial of a Leucine-Metformin-Sildenafil Combination (NS-0200) on Weight and Metabolic Parameters.

Author

Zemel, Michael B., Kolterman, Orville, Rinella, Mary, Vuppalanchi, Raj, Flores, Omar, Barritt, A. Sidney, Siddiqui, Mohammad, Chalasani, Naga, and Barritt, A Sidney 4th

Subjects
RANDOMIZED controlled trials, LEUCINE, SILDENAFIL, SIRTUINS, ENERGY metabolism, BODY weight, COMPARATIVE studies, HYPOGLYCEMIC agents, RESEARCH methodology, MEDICAL cooperation, OBESITY, RESEARCH, STATISTICAL sampling, EVALUATION research, METFORMIN, BLIND experiment, PHOSPHODIESTERASE inhibitors, PHARMACODYNAMICS
Abstract

Objective: Leucine was previously demonstrated to allosterically activate mammalian sirtuin 1 and synergize with other sirtuin 1/AMP-activated protein kinase/nitric oxide pathway activators to modulate energy metabolism. The objective of this study was to evaluate the effects of a triple combination of leucine, metformin, and sildenafil (NS-0200) on body weight and obesity comorbidities in a phase 2 randomized trial.Methods: A total of 91 subjects with obesity were randomized to placebo, low dose (1.1 g leucine/0.5 g metformin/0.5 mg sildenafil), or high dose (1.1 g leucine/0.5 g metformin/1.0 mg sildenafil) twice daily for 16 weeks. Seventy subjects completed the trial and met all a priori compliance criteria. Hypertensive (n = 35) and hypertriglyceridemic (n = 22) subcohorts were also analyzed.Results: NS-0200 dose-responsively reduced weight; high dose reduced weight by 2.4 and 5.0 kg in the full and high-triglyceride cohorts, respectively (P < 0.0001). High-dose NS-0200 treatment also decreased blood pressure (-5.5 mm Hg diastolic pressure; P = 0.011), with greater effects among hypertensive subjects. NS-0200 also significantly reduced triglycerides and hemoglobin A1c. Significant improvement in ≥ 2 comorbidities was exhibited by 54% of subjects in the high-dose arm versus 5% of placebo subjects (P = 0.0009). Treatment-emergent adverse events did not significantly differ among groups.Conclusions: These data support further study of NS-0200 as a therapy for obesity and associated comorbidities. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

39. Su1524 - Sustained Elevation in Alkaline Phosphatase is Associated with Greater Disease Severity in Real World NAFLD

Author

DeLemos, Andrew S., primary, Barritt, A. Sidney, additional, Bhamidimarri, Kalyan R., additional, Landis, Charles, additional, Malahias, Laura, additional, Malespin, Miguel, additional, Schoen, Cheryl, additional, Taunk, Jawahar, additional, Thuluvath, Paul J., additional, Trinh, Huy N., additional, and Tetri, Brent, additional

Published
2018
Full Text
View/download PDF

45. Single Balloon Enteroscopy-Assisted ERCP for Treatment of Cholangitis in a Patient with a Kasai Portoenterostomy

Author

Grimm, Ian S., Orman, Eric S., Barritt, A. Sidney, and Miller, C. Brock

Subjects
Cholangiopancreatography, Endoscopic Retrograde, Young Adult, Postoperative Complications, Biliary Atresia, Cholangitis, Recurrence, Humans, Female, Portoenterostomy, Hepatic, Constriction, Pathologic, Article, Endoscopy, Gastrointestinal
Abstract

Primary therapy for biliary atresia is a surgical hepatoportoenterostomy (Kasai procedure), which has been shown to reduce mortality, but is frequently complicated by ascending cholangitis and the development of biliary cirrhosis. Previously reported therapy for recurrent cholangitis caused by biliary obstruction has included surgical revision and percutaneous biliary drainage, but endoscopic retrograde cholangiopancreatography has not been previously described. Here, we report a patient with recurrent cholangitis after a Kasai procedure and an anastomotic stricture successfully treated with single-balloon enteroscopy-assisted endoscopic retrograde cholangiopancreatography. This novel technique could be considered in patients with this common complication of the Kasai procedure and may impact long-term outcomes in this patient population.

Published
2012

48. Reply

Author

Barritt, A. Sidney, primary, Orman, Eric S., additional, and Hayashi, Paul H., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results